BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37784192)

  • 1. The effect of varicella-zoster virus reactivation on the long-term outcomes of patients undergoing allogeneic hematopoietic stem cell transplantation.
    Li P; Li J; Huang H; Chen X; Lin Y; He G; Xu D
    J Health Popul Nutr; 2023 Oct; 42(1):105. PubMed ID: 37784192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity.
    Vermont CL; Jol-van der Zijde EC; Hissink Muller P; Ball LM; Bredius RG; Vossen AC; Lankester AC
    Transpl Infect Dis; 2014 Apr; 16(2):188-94. PubMed ID: 24438482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose acyclovir for prophylaxis of varicella-zoster virus reactivation after hematopoietic stem cell transplantation in children.
    Tatebe Y; Ushio S; Esumi S; Sada H; Ochi M; Tamefusa K; Ishida H; Fujiwara K; Kanamitsu K; Washio K; Katsube R; Murakawa K; Zamami Y
    Pediatr Blood Cancer; 2022 Dec; 69(12):e29979. PubMed ID: 36151963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.
    Blennow O; Fjaertoft G; Winiarski J; Ljungman P; Mattsson J; Remberger M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1646-9. PubMed ID: 24914821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
    Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral varicella zoster virus (VZV) after allogeneic hematopoietic stem cell transplant (HSCT) in pediatric patients with chronic graft-versus-host disease (cGVHD).
    Peritz DC; Duncan C; Kurek K; Perez-Atayde AR; Lehmann LE
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):931-4. PubMed ID: 19131784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Incidence of Varicella Zoster Virus Disease in Adults Receiving Single-Unit Cord Blood Transplantation.
    Fukushi K; Konuma T; Monna-Oiwa M; Isobe M; Kato S; Kuroda S; Takahashi S; Nannya Y
    Transplant Cell Ther; 2022 Jun; 28(6):339.e1-339.e7. PubMed ID: 35364334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
    Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Japanese single-hospital observational trial with a retrospective case-control analysis of varicella zoster virus reactivation after autologous peripheral blood stem cell transplantation.
    Mawatari M; Isoda A; Miyazawa Y; Sawamura M; Matsumoto M
    Transpl Infect Dis; 2015 Aug; 17(4):544-50. PubMed ID: 26041667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visceral varicella zoster virus infection after allogeneic stem cell transplantation.
    Doki N; Miyawaki S; Tanaka M; Kudo D; Wake A; Oshima K; Fujita H; Uehara T; Hyo R; Mori T; Takahashi S; Okamoto S; Sakamaki H;
    Transpl Infect Dis; 2013 Jun; 15(3):314-8. PubMed ID: 23551634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis.
    Düver F; Weißbrich B; Eyrich M; Wölfl M; Schlegel PG; Wiegering V
    PLoS One; 2020; 15(2):e0228451. PubMed ID: 32017805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Human Herpesvirus-6 Reactivation on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation.
    Aoki J; Numata A; Yamamoto E; Fujii E; Tanaka M; Kanamori H
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2017-22. PubMed ID: 26226409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late-onset visceral varicella-zoster virus infection presented as acute liver failure after allogeneic hematopoietic stem cell transplantation.
    Kikuchi T; Arai M; Koda Y; Kato J; Shimizu T; Katano H; Fujii-Nishimura Y; Sakamoto M; Ebinuma H; Nakamoto N; Kanai T; Okamoto S; Mori T
    Transpl Infect Dis; 2019 Aug; 21(4):e13121. PubMed ID: 31127967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.
    Umezawa Y; Kakihana K; Oshikawa G; Kobayashi T; Doki N; Sakamaki H; Ohashi K
    Transpl Infect Dis; 2014 Apr; 16(2):195-202. PubMed ID: 24438510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
    Thomson KJ; Hart DP; Banerjee L; Ward KN; Peggs KS; Mackinnon S
    Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allotype analysis to distinguish the origin of varicella-zoster virus immunoglobulin G after allogeneic stem cell transplantation.
    Yamazaki R; Nakasone H; Tanaka Y; Sato M; Terasako K; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Machishima T; Kimura S; Kikuchi M; Okuda S; Kako S; Kanda J; Tanihara A; Nishida J; Kanda Y
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1013-20. PubMed ID: 23583826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.